What is Freeline Therapeutics Holdings plc (FRLN)?

Freeline Therapeutics Holdings plc (FRLN) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of FRLN?

The current price of FRLN is $6.49. Prices are updated in real time on Stocks360.

What is FRLN's price-to-earnings (PE) ratio?

FRLN's trailing twelve-month PE ratio is -0.29, based on current price and earnings per share data available on Stocks360.

What is FRLN's market capitalization?

FRLN's market capitalization is $28,283,096.00, placing it in the small-cap tier.

Freeline Therapeutics Holdings plc (FRLN)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$6.49

Market Cap

$28.28M

PE (TTM)

-0.29

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.66

Day Range

$6.48 – $6.49

52-wk Range

$2.11 – $8.75

Avg Volume

N/A

Volume

5.35K

Freeline Therapeutics Holdings plc (FRLN) is a publicly traded company in the Healthcare sector. Latest price: $6.49. Market cap $28.28M. Trailing PE -0.29. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Apr 2, 2024

EPS $-5.22 vs est. $-0.26

Missed by $4.96

Proprietary Signals

Signal snapshot temporarily unavailable.

About Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.29×
P/S (TTM)	0.00×
P/B	0.49×
P/FCF (TTM)	-0.33×
EV / EBITDA	0.13×
EV / Sales	0.00×
Earnings Yield	-346.94%
Free Cash Flow Yield	-301.37%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$13.07M
Net Income (TTM)	-$98.12M
Free Cash Flow (TTM)	-$85.24M
Net Debt	-$41.35M
Working Capital	$36.66M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-102.94%
Return on Invested Capital	-168.75%